Thaum Lub Ib Hlis 28, 2026, Shandong Shengdi Pharmaceutical Co., Ltd., ib lub chaw muag khoom ntawm Hengrui Pharmaceutical, tau txais "Cov Ntawv Pom Zoo Tshuaj Kho Mob" uas tau muab los ntawm National Medical Products Administration, pom zoo rau lub tuam txhab kev ywj pheej tsim Chav Kawm 1 lub tswv yim tshiab ntawm qhov ncauj me me molecule GLP-1 RS-1 receptors rau kev sim tshuaj. rau qhov qhia txog kev kub siab ua ke nrog rog lossis rog. Glucagon zoo li peptide-1 receptor (GLP-1 R) agonists yog cov chav kawm tshiab ntawm hypoglycemic thiab cov tshuaj poob phaus.
1. General Specification (hauv Tshuag)
(1) API (Ntshiab hmoov)
(2) Tablet
(3) Capsule
(4) Txhaj tshuaj
(5) Ua kua dej
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
Internal Code: BM-3-094
GLP-1 CAS Nr .: 87805-34-3
Lub khw tseem ceeb: Tebchaws Asmeskas, Australia, Brazil, Nyiv, Lub Tebchaws Yelemees, Indonesia, UK, New Zealand, Canada thiab lwm yam.
Chaw tsim tshuaj paus: BLOOM TECH Xi'an Hoobkas
Peb muabGLP-1 Txhaj, thov xa mus rau lub vev xaib hauv qab no kom paub meej specifications thiab cov ntaub ntawv khoom.
Khoom siv:https://www.bloomtechz.com/oem-odm/injection/glp-1-injections.html
Nyob rau hauv xyoo tas los no, cov kev tshawb fawb tau pom tias GLP-1 R agonists tuaj yeem qhib GLP-1 receptors, txhawb cov zis sodium excretion, txhim kho endothelial muaj nuj nqi, inhibit sympathetic nervous kev ua si, tswj renin angiotensin aldosterone system (RAAS), thiab yog li siv cov tshuaj tiv thaiv. HRS-7535 ntsiav tshuaj yog ib qho tshiab ntawm qhov ncauj me me molecule GLP-1R agonist, uas tuaj yeem tsis tsuas yog txhawb nqa insulin tso tawm ntawm pancreas thiab txo glucagon secretion thiab inhibit plab hnyuv tawm los ntawm kev ua kom tib neeg GLP-1R, tab sis kuj tuaj yeem siv los kho hom 2 mob ntshav qab zib thiab rog los ntawm kev cuam tshuam lub hauv nruab nrab paj hlwb kom txo tau lub zog satiety thiab kev noj qab haus huv. Tam sim no, tsis muaj qhov ncauj me me molecule GLP-1R agonists ntawm lub khw thoob ntiaj teb.
Novartis 'lub ntiaj teb thawj me me cuam tshuam RNA cov roj cholesterol txo cov tshuaj (Ingersoll Rand Sodium Txhaj) tau pom zoo rau qhov qhia tshiab
Thaum Lub Ib Hlis 28, 2026, Novartis tshaj tawm tias nws cov tshuaj txo cov roj cholesterol, Leclerc 8 (Ingersoll Rand Sodium Txhaj), tau pom zoo los ntawm Tuam Tshoj National Medical Products Administration ua kev kho mob ntxiv rau kev noj haus. Nws yog siv los ua ib qho kev kho mob monotherapy rau cov neeg laus uas muaj thawj hypercholesterolemia (tsis yog tsev neeg) lossis sib xyaw dyslipidemia kom txo qis -cov roj lipoprotein ceev (LDL-C). Qhov no txhais tau hais tias Ingersoll Rand Sodium Txhaj tshuaj ntxiv npog ntau cov neeg mob uas muaj dyslipidemia xav tau, raws li cov lus pom zoo yav dhau los rau kev sib xyaw nrog statins lossis lwm yam lipid - txo qis kev kho mob.
Raws li lub ntiaj teb thawj zaug thiab tam sim no tsuas yog pom zoo cuam tshuam me me RNA cov roj cholesterol txo cov tshuaj tiv thaiv PCSK9, txoj kev tswj hwm ntawm "ob txhaj tshuaj ib xyoos" ntawm Ingersoll Rand Sodium Txhaj yog xav kom txhim kho kev ua raws li kev kho mob thiab ntev - lub sij hawm ua raws li LDL -C, pab ua kom tiav ntev - lipids tswj cov ntshav.
Raws li cov tshuaj tshiab los txo LDL -C, Ingersoll Rand tuaj yeem thaiv cov synthesis ntawm precursor protein convertase PCSK9 protein, uas ua rau kom nce LDL -C, los ntawm qhov chaw, yog li stabilizing lub sij hawm ntev - txo qis LDL-C qib. Raws li V-MONO Tuam Tshoj txoj kev tshawb fawb ua los ntawm Chuanqi Clinical, piv nrog cov placebo, hauv cov neeg mob uas muaj kev pheej hmoo qis / nruab nrab ntawm ASCVD uas tsis tau txais lipid- txo qis kev kho mob, kev siv Ingersoll Rand monotherapy ua tiav kev kho mob thiab kev txheeb xyuas qhov tseem ceeb LDL -C txo cov txiaj ntsig piv rau cov placebo.
Lekewei tau txais kev pom zoo thawj zaug hauv Suav teb thaum Lub Yim Hli 2023 raws li kev noj zaub mov ntxiv rau kev kho mob ntawm cov neeg laus cov neeg mob uas muaj thawj hypercholesterolemia (heterozygous tsev neeg thiab tsis yog tsev neeg) lossis sib xyaw dyslipidemia. Nws suav nrog kev siv statins ib leeg lossis ua ke nrog lwm cov lipid- txo cov kev kho mob hauv cov neeg mob uas tsis tuaj yeem ua tiav LDL-C (tsawg-cov roj lipoprotein cholesterol) ntom ntom) lub hom phiaj txawm tias tau txais koob tshuaj ntau tshaj plaws ntawm statins, nrog rau cov neeg mob uas tsis quav ntsej lossis tsis pom zoo rau statins. Cov lus qhia tau hais los saum toj no tau suav nrog hauv "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025)" rau lub Kaum Ob Hlis 7, 2025. Cov tshuaj qhia ib leeg pom zoo rau lub sijhawm no tseem tsis tau muaj nyob rau hauv qhov kev them nyiaj pov hwm kho mob.
Huadong Pharmaceutical thiab Shian Biotechnology sib koom tes los tsim kho siRNA thiab nkag mus rau theem kev tshawb fawb txog kev kho mob.
Thaum Lub Ib Hlis 29, 2026, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (txuas ntxiv mus hu ua "Huadong Pharmaceutical"), ib qho tag nrho -tus tswv lag luam ntawm Huadong Pharmaceutical Co., Ltd. (SZ. 000963), thiab Suzhou Shian Biotechnology Ltd. Biotechnology") tau tshaj tawm tias lawv txoj haujlwm kev koom tes hauv kev sib koom tes, siRNA txoj kev kho tshiab rau lub cev poob phaus, tau ua tiav qhov kev lees paub ntawm cov neeg sib tw preclinical compounds (PCC) thiab tau nkag mus rau theem kev tshawb fawb preclinical.
Huadong Pharmaceutical thiab Shian Biotechnology vam khom rau kev tshawb fawb thiab kev loj hlob zoo ntawm ob tog kom tsom mus rau qhov kev xav tau ntawm kev kho mob tsis zoo ntawm cov kab mob metabolic xws li rog rog thiab tsis yog - cawv fatty siab kab mob (MASH), thiab ua kom txoj kev loj hlob ntawm ib tiam tshiab ntawm cov phiaj xwm kho mob metabolic. Qhov kev nce qib no yog qhov tseem ceeb tshaj plaws rau ob tog txij li tau ua tiav daim ntawv cog lus kev koom tes thaum ntxov 2025.
Ob tog yuav sai sai ua qhov project mus rau theem kev tshawb fawb preclinical, thiab xav tias yuav tsim ib tiam tshiab ntawm kev kho mob me me nucleic acid hauv kev poob phaus; Shian Biotechnology muaj txoj cai kom tau txais cov nyiaj them poob haujlwm, kev them nyiaj tseem ceeb, thiab feem ntau ntawm kev sib koom daim ntawv tso cai txawv teb chaws.
Tus yam ntxwv ntawm "ib- kev tswj hwm lub sijhawm thiab kev ua haujlwm ntev- lub sijhawm ua haujlwm" ntawm siRNA zoo kawg nkaus ua tau raws li kev xav tau ntawm kev kho mob ntev - lub sijhawm tswj cov kab mob metabolic. Shian Biotech, vam khom rau nws tus kheej tsim AI raws li siRNA sib lawv liag tsim platform, eSAFE tshuaj hloov kho ceg, thiab STORK-L GalINAc coupling xa tshuab thiab lwm yam tseem ceeb zoo hauv siRNA tshuaj txoj kev loj hlob, tau ua hauj lwm ze nrog lub R&D pab neeg ntawm East China Medicine kom ua tiav cov kev kho mob tshwj xeeb siRNA molecules.
Cov ntaub ntawv sim ua ntej qhia tau hais tias nws muaj cov txiaj ntsig zoo hauv kev txo lub cev hnyav thiab txhim kho cov piam thaj thiab lipid metabolism, nrog kev nyab xeeb txhua hnub thiab muaj peev xwm los ua "zoo tshaj plaws hauv chav kawm" tshuaj. Nyob rau hauv lub neej yav tom ntej, Huadong Pharmaceutical yuav siv nws txoj kev loj hlob muaj peev xwm, chaw kho mob, thiab kev lag luam kev lag luam nyob rau hauv cov kab mob metabolic kom coj mus kuaj sim tsim, sau npe thiab daim ntawv thov, thiab nthuav dav nws lub lag luam thoob ntiaj teb. Ob tog yuav txuas ntxiv mus ua kom lub chaw kho mob validation thiab industrialization txheej txheem ntawm no txoj kev kho mob los ntawm complementary zoo.
